US and UK Finalize Tariff-Free Pact on Medicines.
The UK and US have signed a landmark commercial pact that will keep no import taxes on British drug exports going into the American market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to raise spending on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these vital products will remain at zero for a period of 36 months.
This development follows earlier threats to significantly raise tariffs on patented pharmaceutical imports, with figures floated up to 100%.
"This agreement between the United Kingdom bolsters the international landscape for new treatments and introduces long-overdue fairness to U.S.–U.K. medicine commerce," a release noted.
Economic Importance
Drugs constitute one of the UK's biggest export categories to the America, which is clearly the largest destination for large British pharmaceutical firms.
Export figures reveal that in the 12 months to the end of last September, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This amount represented 17.4% of British export trade in that timeframe.
"This guarantee protects work, increases funding and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official commented.
Key British Pledges
The agreement includes several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a target to double total public funding on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be limited at 15%. Previously, rebates were more than 20%.
Industry Background
The pact follows a long-running tension between the sector and the UK government over medicine costs and NHS adoption.
The disagreement were heightened by claims that US patients were charged several times more for the same drugs than patients in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while major funding commitments have been announced toward US facilities.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the past decade.